UniQuest Trials - LARVOL Sigma

41 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Curcusome-RA / UniQuest, J&J

ACTRN12610000373077: A dendritic cell vaccine to suppress the immune response to citrullinated antigen in rheumatoid arthritis

Active, not recruiting

Uniquest, National Health and Medical Research Council (NHMRC)

Rheumatoid arthritis

Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine) / UniQuest

NCT01998178: Immune Response and Safety Study of Human Papillomavirus (HPV) Vaccine in HIV-infected Pre-adolescent in Kenya

Active, not recruiting

180

RoW

Quadrivalent HPV Vaccine, Gardasil

Kenyatta National Hospital, University of Washington, Merck

Genital Warts, Cervical Cancer

08/15

12/15

2008-006773-32: A Phase IV, randomised study to evaluate the immune responses of UK adolescent girls receiving Cervarix(TM) or Gardasil(TM) Human Papillomavirus vaccines

Ongoing

400

Europe

Cervarix, Gardasil, Cervarix, Gardasil, Cervarix, Gardasil

Health Protection Agency

This study will investigate vaccines that prevent premalignant cervical lesions and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18. This study will investigate whether immunisation against infection with HPV 16 and 18 may impact on other oncogenic HPV types, through cross-protection.

2013-002009-70: HPV vaccination after treatment of anal intraepithelial neoplasia HPV vaccinatie na behandeling van anale dysplasie

Ongoing

125

Europe

Gardasil, Gardasil

Academic Medical Center, The Netherlands Organisation for Health Research and Development

Intra-anal high-grade anal intraepithelial neoplasia (AIN) (grade 2-3) in HIV+ men that was successfully treated in the past year with conventional cauterization, cryotherapy, or other forms of local treatment.

2014-003177-42: Study in several countries to asess the proportion of adult women (30-45 years) WHO accept to receive the HPV vaccine, the reasons to accept it and how many of these women who receive three doses of the vaccine.

Ongoing

500

Europe

Gardasil, Gardasil

Catalan Institute of Oncology, Ghent University Hospital, European Commission, 7th framework programme, Sanofi Pasteur MSD SNC, European Commission, 7 th framework programme, GlaxoSmithKline Biologicals S.A., Sanofi Pasteur MSD SNC., Ghent University Hospital

Cervical cancer

NCT00923702: Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India

Active, not recruiting

22729

RoW

Prophylactic quadrivalent HPV vaccine Merck (Gardasil®), Gardasil®

Partha Basu, All India Institute of Medical Sciences, New Delhi, Cancer Foundation of India, Christian Fellowship Community Health Centre, Deutsches Krebsforschungszentrum (DKFZ), Gujarat Cancer & Research Institute, Jehangir Clinical Development Centre, MNJ Institute of Oncology & Regional cancer Center, Rajiv Gandhi Centre for Biotechnology, Tata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital, Tata Memorial Centre

Cervical Cancer, Cervical Precancerous Lesions

01/17

07/26

NCT06345885: Immunogenicity and Safety of One Dose of HPV Vaccine

Completed

200

RoW

HPV vaccine

Xiamen Innovax Biotech Co., Ltd

Human Papillomavirus Vaccines

01/24

NCT04590521: HPV Vaccine Immunity in High-risk Women

Completed

RoW

Gardasil®, Merck

Murdoch Childrens Research Institute, London School of Hygiene and Tropical Medicine, National Institute of Hygiene and Epidemiology, Vietnam

HPV Infection

04/23

NCT05435209: Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents

Completed

158

RoW

Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine, Gardasil-4

University of Washington, Merck Sharp & Dohme LLC

HPV Infection, HPV Vaccination

10/23

ChiCTR2300069209: Study on the safety and immunogenicity of the immunization procedure for one dose of HPV vaccine

Recruiting

200

Inoculate 1 dose of cecoline ;Inoculate with 1 dose of Gardasil

Fujian Provincial Center for Disease Control and Prevention; Xiamen Wantai Canghai Biology Technology Co., Ltd., Self-raised

cervical carcinoma

NCT05031078: Assessing Durable Antibody Response to HPV Vaccination

Active, not recruiting

Gardasil, HPV vaccine, Lidocaine injections

Emory University

HPV

10/24

05/26

Add-Vacc, NCT04953130: Adding Male Single Dose HPV Vaccination to Female HPV Vaccination in Tanzania

Active, not recruiting

10400

RoW

Gardasil® HPV vaccine, 4-valent HPV vaccine

London School of Hygiene and Tropical Medicine, Mwanza Intervention Trials Unit, National Institute for Medical Research, York Biomedical Research Institute, Hull York Medical School, University of York, Cancer Epidemiology Research Programme Institut Català d' Oncologia, Karolinska Institute Department of Laboratory Medicine, Department of Pathology University of Cambridge

HPV Infection, Vaccine Preventable Disease

11/25

10/26

FUTURE II, NCT00092534: Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)

Active, not recruiting

12167

Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine, V501, qHPV vaccine, Matching Placebo

Merck Sharp & Dohme LLC

Cervical Cancer, Genital Warts

07/07

06/25

V501-213, NCT03493542 / 2023-001144-29: A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years

Completed

766

RoW

V501, (Gardasil®) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, qHPV

Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC

Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ

10/23

NCT05027776: Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

Recruiting

1348

RoW

2-doses Group among 9-14 years, 3-doses Group among 9-19 years, 3-doses Group among 20-26 years

Shanghai Bovax Biotechnology Co., Ltd., Chongqing Bovax Biopharmaceutical Co., Ltd.

HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart, CIN1, CIN2, CIN3

11/23

09/26

NCT05668572: A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

Active, not recruiting

12000

RoW

Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli), Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)（GARDASIL®）

Beijing Health Guard Biotechnology, Inc

Human Papillomavirus Infection

07/22

02/23

PRIMAVERA-ESCUDDO, NCT03728881: Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the Trial

Completed

1240

RoW

Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine, Gardasil, Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle vaccine, quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccine, Recombinant Human Papillomavirus (HPV) Quadrivalent Vaccine, V501, Recombinant Human Papillomavirus Bivalent Vaccine, Cervarix, GSK-580299, HPV 16/18 L1 VLP/AS04 VAC, HPV-16/18 VLP/AS04 Vaccine, Human Papillomavirus 16/18 L1 Virus-Like Particle/AS04 Vaccine, Human Papillomavirus Bivalent Types 16 and 18 Vaccine, Recombinant, Human Papillomavirus Vaccine L1 16,18, Human Papillomavirus Vaccine, L1 Type 16, 18, Recombinant HPV Bivalent Vaccine

National Cancer Institute (NCI)

Human Papillomavirus-Related Cervical Carcinoma

09/22

04/24

NCT05584332: A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females

Terminated

3131

RoW

Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha), Placebo

Shanghai Bovax Biotechnology Co., Ltd.

Cervical Cancer, Genital Wart, CIN1, CIN2, CIN3, Vain I, Vain III, Vin I, Vin II, Vin III, AIS, VAIN - Vaginal Intraepithelial Neoplasia 2

03/23

TheraVACCS, NCT02750202: Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts

Active, not recruiting

RoW

Quadrivalent HPV vaccine, Gardasil, 4 HPV vaccine, q HPV vaccine, Hepatitis B vaccine, Hep B vaccine

University of Pretoria, University of Stellenbosch

Genital Warts

05/25

07/25

2023-001144-29: Immunobridging study of V501 in Chinese girls and young women

Not yet recruiting

766

RoW

Suspension for injection in pre-filled syringe, Gardasil®

Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC

Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ, Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ, Diseases [C] - Cancer [C04]

NCT04508309: Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls

Completed

1025

RoW

Cecolin®, Gardasil®

PATH, International Centre for Diarrhoeal Disease Research, Bangladesh, Malaria Research Centre, Agogo Presbyterian Hospital, Ghana, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., USA, The Emmes Company, LLC, Xiamen Innovax Biotech Co., Ltd

Cervical Cancer

12/23

NCT06281119: Clinical Study to Evaluate SIIPL QHPV Vaccine (CERVAVAC®) in Women Living with HIV Aged 15-25 Years

Not yet recruiting

450

RoW

Cervavac as three dose regimen, Cervavac as two dose regimen, Gardasil as three dose regimen

Serum Institute of India Pvt. Ltd., Bill and Melinda Gates Foundation

Human Papillomavirus Infection

06/26

12/26

V503-023, NCT03998254: Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years

Active, not recruiting

6000

RoW

V503, Gardasil

Merck Sharp & Dohme LLC

Papillomavirus Infections

03/28

2011-006002-27: Multicentre trial evaluating the immunogenicity of HPV vaccination in girls on immunosuppressive therapy. Essai clinique multicentrique évaluant la réponse immunologique de la vaccination contre l’infection par les papillomavirus humains (HPV) 6, 11, 16, 18 chez des jeunes filles recevant un traitement immunosuppresseur

Ongoing

Europe

Suspension for injection in pre-filled syringe, GARDASIL

CHU de Bordeaux, PHRC Nationnal 2011

Infection by HPV 6, 11, 16, 18 Infection par les papillomavirus humains (HPV) 6, 11, 16, 18, Diseases [C] - Virus Diseases [C02]

2013-002137-38: A clinical study evaluating the safety, tolerability, and immune response to HPV vaccine given together with Bivalent RLP2086 vaccine in healthy subjects ≥ 11 to < 18 years of age.

2500

Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein, PF-05212366,

Pfizer Inc, Pfizer Inc

Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MnB) in adolescents and young adults, aged 10 through 25 years.

GINI, NCT02363660: Gardasil Immunogenicity With Needle-Free Injection

Completed

150

RoW

GINI

Thai Red Cross AIDS Research Centre, University of California, San Francisco

HIV

12/22

02/23

RIFT-HPV, NCT05334706: A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV

Recruiting

Europe

Nonavalent HPV vaccine (9vHPV/Gardasil-9™).

Miquel Angel Pavon Ribas, Hospital del Mar, Catalan Institute of Health

Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Human Papillomavirus (HPV) Infections, High-risk HPV, HPV-16/ 18

05/24

NCT06142461: Safety and Immunogenicity of HPV Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System

Withdrawn

480

RoW

Gardasil, Gardasil PFS, 0.5mL, Gardasil vial, 0.5mL, Gardasil vial, 0.2mL, PharmaJet Stratis® Needle-Free Injection System, Stratis, PharmaJet Tropis® Needle-Free Injection System, Tropis

PharmaJet, Inc., National Institutes of Health (NIH), National Cancer Institute (NCI)

Vaccine Reaction

12/24

04/25

NCT00505063: Prospective Trial of Vaccine Responses in Childhood Cancer Survivors

Completed

Immunization Schedule patients <7 years., vaccine, Prevnar 13, vaccine, Menactra II, Measles, mumps, rubella, MMR, Live, attenuated varicella vaccine, Varivax, Quadrivalent HPV Recombinant Vaccine, Immunization Schedule patients > or = to 7 years and <11 years of age, Immunization Schedule patients > or = to 11 years of age

Memorial Sloan Kettering Cancer Center

Childhood Cancer, Multiple Diseases

06/25

PROTECT, NCT06624839: Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV

Recruiting

120

Human papillomavirus (HPV) vaccine, 9-valent, Gardasil9

University of Maryland, Baltimore

Human Papilloma Virus, Anal Dysplasia, HIV

01/27

01/28

NCT03855150: Trial of HPV Vaccine in Healthy Adult and Adolescent Female

Recruiting

1/2

200

RoW

NBP615 (SK bioscience HPV vaccine), Gardasil® (Merck & Co)

International Centre for Diarrhoeal Disease Research, Bangladesh, SK Bioscience Co., Ltd.

Human Papilloma Virus Vaccine

12/19

ACTRN12612000362897: Pilot Study of the V501 Product - Protocol 501: A pilot study of the ForSight Ocular System on Safety and Efficacy in Anterior Segment Eye Disease in Australia

Active, not recruiting

ForSight VISION5, Inc, ForSight VISION5, Inc

Anterior segment eye disease

NCT04921111: A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years

Recruiting

240

RoW

SCT1000, Recombinant 14 valent Human Papillomavirus Vaccine, Gardasil®9, Recombinant 9 valent human papillomavirus vaccine, placebo, aluminium phosphate, Gardasil®, Recombinant 4 valent human papillomavirus vaccine

Sinocelltech Ltd.

HPV Infection Vaccine Safety SCT1000

07/22

10/22

AIR:RRP, NCT03465280: Airway Intervention Registry (AIR): Recurrent Respiratory Papillomatosis (RRP)

Recruiting

N/A

400

Europe

Microdebrider, Cold-steel surgery (forceps), Carbon dioxide laser, Potassium titanyl phosphate (KTP) laser, Pulsed dye laser, Radiofrequency ablation, Monopolar suction diathermy, Plasma coagulation, Other, Adjuvant therapies, Acyclovir, Artemisinin, Bevacizumab (Avastin), Celecoxib (Celebrex), Cidofovir, Cimetidine, Di-indolmethane (DIM), Gardasil, Indole-3-carbinol (I3C), alpha-Interferon, PEG-Interferon, Methotrexate, Retinoic acid (isotretinoin), Ribavarin

Newcastle-upon-Tyne Hospitals NHS Trust, Alder Hey Children's NHS Foundation Trust, National Institute for Health Research, United Kingdom

Recurrent Respiratory Papillomatosis, Human Papilloma Virus

08/22

NCT05761002: Human Papilloma Virus Genotypes and Treatment Outcomes of Intralesional Immunotherapy of Anogenital Warts

Recruiting

N/A

RoW

the Quadrivalent Vaccine (Gardasil)

Zagazig University

Human Papilloma Virus, Anogenital Wart

06/23

07/23

V503-021, NCT02653118: Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women

Active, not recruiting

N/A

4453

V503, GARDASIL

Merck Sharp & Dohme LLC

Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts, Human Papillomavirus Infection

01/40

NCT06650956: Integration to Improve Adolescent Health and HPV Vaccination in Laos

Recruiting

N/A

700

RoW

Integrated HPV and SRH Service Package, Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant, Gardasil

Health Poverty Action, Gavi, The Vaccine Alliance, University of Health Sciences Laos

Healthy, Adolescents, Integrated, Community-Health Systems, HPV Vaccines, Sexual and Reproductive Health, Knowledge, Attitude, Health Workers

05/25

ChiCTR2300072294: Demonstration Project of Cervical Cancer Elimination and Comprehensive Prevention and Control of Breast Cancer in Low Medical Resource Areas in China

Not yet recruiting

N/A

553000

Cervical cancer screening ;Breast Cancer Screening ;HPV vaccine: bivalent recombinant human papillomavirus vaccine (Escherichia coli) produced by Xiamen Wan Tai Canghai Biotechnology Co., Ltd. (trade name: Cecolin, Xinkening); Tetravalent recombinant human papillomavirus-like particle vaccine (Saccharomyces cerevisiae) produced by Merck, USA (trade name: Gardasil, Jiadaxiu); Bivalent human papillomavirus vaccine (Pichia pastoris) produced by Yunnan watson biological Technology Co., Ltd. (trade name: Wozehui)

School of Population Medicine and Public Health, Chinese Academy of Medical Sciences Peking Union Medical College; School of Population Medicine and Public Health, Chinese Academy of Medical Sciences Peking Union Medical College, Tencent Sustainable Social Value Division

Cervical Cancer and Breast Cancer

ChiCTR2100052313: Effectiveness of the prophylactic quadrivalent human papillomavirus vaccine in Chinese female: 10- and 15-year follow-up of the phase 3, double-blind, randomized, placebo-controlled V501-041 study

Not yet recruiting

N/A

1080

N/A ;N/A ;N/A

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, MSD R&D(China) Co. LTD

Cervical Cancer

NCT04920526: Effectiveness and B-memory Cell Response to QHPV Vaccine 9-years Post-vaccination Among HIV-infected Boys and Girls

Not yet recruiting

N/A

135

Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine, Gardasil

Kenya Medical Research Institute, University of Washington

HPV-Related Carcinoma

12/22

NCT05371353: Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine

Recruiting

N/A

600

RoW

Shanghai Bovax Biotechnology Co., Ltd.

HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart, CIN1, CIN2, CIN3

05/27

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Curcusome-RA / UniQuest, J&J

ACTRN12610000373077: A dendritic cell vaccine to suppress the immune response to citrullinated antigen in rheumatoid arthritis

Active, not recruiting

Uniquest, National Health and Medical Research Council (NHMRC)

Rheumatoid arthritis

Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine) / UniQuest

NCT01998178: Immune Response and Safety Study of Human Papillomavirus (HPV) Vaccine in HIV-infected Pre-adolescent in Kenya

Active, not recruiting

180

RoW

Quadrivalent HPV Vaccine, Gardasil

Kenyatta National Hospital, University of Washington, Merck

Genital Warts, Cervical Cancer

08/15

12/15

2008-006773-32: A Phase IV, randomised study to evaluate the immune responses of UK adolescent girls receiving Cervarix(TM) or Gardasil(TM) Human Papillomavirus vaccines

Ongoing

400

Europe

Cervarix, Gardasil, Cervarix, Gardasil, Cervarix, Gardasil

Health Protection Agency

2013-002009-70: HPV vaccination after treatment of anal intraepithelial neoplasia HPV vaccinatie na behandeling van anale dysplasie

Ongoing

125

Europe

Gardasil, Gardasil

Academic Medical Center, The Netherlands Organisation for Health Research and Development

Ongoing

500

Europe

Gardasil, Gardasil

Cervical cancer

NCT00923702: Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India

Active, not recruiting

22729

RoW

Prophylactic quadrivalent HPV vaccine Merck (Gardasil®), Gardasil®

Cervical Cancer, Cervical Precancerous Lesions

01/17

07/26

NCT06345885: Immunogenicity and Safety of One Dose of HPV Vaccine

Completed

200

RoW

HPV vaccine

Xiamen Innovax Biotech Co., Ltd

Human Papillomavirus Vaccines

01/24

NCT04590521: HPV Vaccine Immunity in High-risk Women

Completed

RoW

Gardasil®, Merck

Murdoch Childrens Research Institute, London School of Hygiene and Tropical Medicine, National Institute of Hygiene and Epidemiology, Vietnam

HPV Infection

04/23

NCT05435209: Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents

Completed

158

RoW

Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine, Gardasil-4

University of Washington, Merck Sharp & Dohme LLC

HPV Infection, HPV Vaccination

10/23

ChiCTR2300069209: Study on the safety and immunogenicity of the immunization procedure for one dose of HPV vaccine

Recruiting

200

Inoculate 1 dose of cecoline ;Inoculate with 1 dose of Gardasil

Fujian Provincial Center for Disease Control and Prevention; Xiamen Wantai Canghai Biology Technology Co., Ltd., Self-raised

cervical carcinoma

NCT05031078: Assessing Durable Antibody Response to HPV Vaccination

Active, not recruiting

Gardasil, HPV vaccine, Lidocaine injections

Emory University

HPV

10/24

05/26

Add-Vacc, NCT04953130: Adding Male Single Dose HPV Vaccination to Female HPV Vaccination in Tanzania

Active, not recruiting

10400

RoW

Gardasil® HPV vaccine, 4-valent HPV vaccine

HPV Infection, Vaccine Preventable Disease

11/25

10/26

FUTURE II, NCT00092534: Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)

Active, not recruiting

12167

Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine, V501, qHPV vaccine, Matching Placebo

Merck Sharp & Dohme LLC

Cervical Cancer, Genital Warts

07/07

06/25

Completed

766

RoW

V501, (Gardasil®) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, qHPV

Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC

Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ

10/23

NCT05027776: Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

Recruiting

1348

RoW

2-doses Group among 9-14 years, 3-doses Group among 9-19 years, 3-doses Group among 20-26 years

Shanghai Bovax Biotechnology Co., Ltd., Chongqing Bovax Biopharmaceutical Co., Ltd.

HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart, CIN1, CIN2, CIN3

11/23

09/26

NCT05668572: A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

Active, not recruiting

12000

RoW

Beijing Health Guard Biotechnology, Inc

Human Papillomavirus Infection

07/22

02/23

PRIMAVERA-ESCUDDO, NCT03728881: Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the Trial

Completed

1240

RoW

National Cancer Institute (NCI)

Human Papillomavirus-Related Cervical Carcinoma

09/22

04/24

NCT05584332: A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females

Terminated

3131

RoW

Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha), Placebo

Shanghai Bovax Biotechnology Co., Ltd.

Cervical Cancer, Genital Wart, CIN1, CIN2, CIN3, Vain I, Vain III, Vin I, Vin II, Vin III, AIS, VAIN - Vaginal Intraepithelial Neoplasia 2

03/23

TheraVACCS, NCT02750202: Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts

Active, not recruiting

RoW

Quadrivalent HPV vaccine, Gardasil, 4 HPV vaccine, q HPV vaccine, Hepatitis B vaccine, Hep B vaccine

University of Pretoria, University of Stellenbosch

Genital Warts

05/25

07/25

2023-001144-29: Immunobridging study of V501 in Chinese girls and young women

Not yet recruiting

766

RoW

Suspension for injection in pre-filled syringe, Gardasil®

Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC

NCT04508309: Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls

Completed

1025

RoW

Cecolin®, Gardasil®

Cervical Cancer

12/23

NCT06281119: Clinical Study to Evaluate SIIPL QHPV Vaccine (CERVAVAC®) in Women Living with HIV Aged 15-25 Years

Not yet recruiting

450

RoW

Cervavac as three dose regimen, Cervavac as two dose regimen, Gardasil as three dose regimen

Serum Institute of India Pvt. Ltd., Bill and Melinda Gates Foundation

Human Papillomavirus Infection

06/26

12/26

V503-023, NCT03998254: Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years

Active, not recruiting

6000

RoW

V503, Gardasil

Merck Sharp & Dohme LLC

Papillomavirus Infections

03/28

Ongoing

Europe

Suspension for injection in pre-filled syringe, GARDASIL

CHU de Bordeaux, PHRC Nationnal 2011

Infection by HPV 6, 11, 16, 18 Infection par les papillomavirus humains (HPV) 6, 11, 16, 18, Diseases [C] - Virus Diseases [C02]

2013-002137-38: A clinical study evaluating the safety, tolerability, and immune response to HPV vaccine given together with Bivalent RLP2086 vaccine in healthy subjects ≥ 11 to < 18 years of age.

2500

Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein, PF-05212366,

Pfizer Inc, Pfizer Inc

Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MnB) in adolescents and young adults, aged 10 through 25 years.

GINI, NCT02363660: Gardasil Immunogenicity With Needle-Free Injection

Completed

150

RoW

GINI

Thai Red Cross AIDS Research Centre, University of California, San Francisco

HIV

12/22

02/23

RIFT-HPV, NCT05334706: A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV

Recruiting

Europe

Nonavalent HPV vaccine (9vHPV/Gardasil-9™).

Miquel Angel Pavon Ribas, Hospital del Mar, Catalan Institute of Health

Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Human Papillomavirus (HPV) Infections, High-risk HPV, HPV-16/ 18

05/24

NCT06142461: Safety and Immunogenicity of HPV Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System

Withdrawn

480

RoW

Gardasil, Gardasil PFS, 0.5mL, Gardasil vial, 0.5mL, Gardasil vial, 0.2mL, PharmaJet Stratis® Needle-Free Injection System, Stratis, PharmaJet Tropis® Needle-Free Injection System, Tropis

PharmaJet, Inc., National Institutes of Health (NIH), National Cancer Institute (NCI)

Vaccine Reaction

12/24

04/25

NCT00505063: Prospective Trial of Vaccine Responses in Childhood Cancer Survivors

Completed

Memorial Sloan Kettering Cancer Center

Childhood Cancer, Multiple Diseases

06/25

PROTECT, NCT06624839: Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV

Recruiting

120

Human papillomavirus (HPV) vaccine, 9-valent, Gardasil9

University of Maryland, Baltimore

Human Papilloma Virus, Anal Dysplasia, HIV

01/27

01/28

NCT03855150: Trial of HPV Vaccine in Healthy Adult and Adolescent Female

Recruiting

1/2

200

RoW

NBP615 (SK bioscience HPV vaccine), Gardasil® (Merck & Co)

International Centre for Diarrhoeal Disease Research, Bangladesh, SK Bioscience Co., Ltd.

Human Papilloma Virus Vaccine

12/19

ACTRN12612000362897: Pilot Study of the V501 Product - Protocol 501: A pilot study of the ForSight Ocular System on Safety and Efficacy in Anterior Segment Eye Disease in Australia

Active, not recruiting

ForSight VISION5, Inc, ForSight VISION5, Inc

Anterior segment eye disease

NCT04921111: A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years

Recruiting

240

RoW

Sinocelltech Ltd.

HPV Infection Vaccine Safety SCT1000

07/22

10/22

AIR:RRP, NCT03465280: Airway Intervention Registry (AIR): Recurrent Respiratory Papillomatosis (RRP)

Recruiting

N/A

400

Europe

Newcastle-upon-Tyne Hospitals NHS Trust, Alder Hey Children's NHS Foundation Trust, National Institute for Health Research, United Kingdom

Recurrent Respiratory Papillomatosis, Human Papilloma Virus

08/22

NCT05761002: Human Papilloma Virus Genotypes and Treatment Outcomes of Intralesional Immunotherapy of Anogenital Warts

Recruiting

N/A

RoW

the Quadrivalent Vaccine (Gardasil)

Zagazig University

Human Papilloma Virus, Anogenital Wart

06/23

07/23

V503-021, NCT02653118: Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women

Active, not recruiting

N/A

4453

V503, GARDASIL

Merck Sharp & Dohme LLC

Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts, Human Papillomavirus Infection

01/40

NCT06650956: Integration to Improve Adolescent Health and HPV Vaccination in Laos

Recruiting

N/A

700

RoW

Integrated HPV and SRH Service Package, Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant, Gardasil

Health Poverty Action, Gavi, The Vaccine Alliance, University of Health Sciences Laos

Healthy, Adolescents, Integrated, Community-Health Systems, HPV Vaccines, Sexual and Reproductive Health, Knowledge, Attitude, Health Workers

05/25

ChiCTR2300072294: Demonstration Project of Cervical Cancer Elimination and Comprehensive Prevention and Control of Breast Cancer in Low Medical Resource Areas in China

Not yet recruiting

N/A

553000

Cervical Cancer and Breast Cancer

Not yet recruiting

N/A

1080

N/A ;N/A ;N/A

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, MSD R&D(China) Co. LTD

Cervical Cancer

NCT04920526: Effectiveness and B-memory Cell Response to QHPV Vaccine 9-years Post-vaccination Among HIV-infected Boys and Girls

Not yet recruiting

N/A

135

Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine, Gardasil

Kenya Medical Research Institute, University of Washington

HPV-Related Carcinoma

12/22

NCT05371353: Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine

Recruiting

N/A

600

RoW

Shanghai Bovax Biotechnology Co., Ltd.

HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart, CIN1, CIN2, CIN3

05/27

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites